ALX Oncology

4 articles with ALX Oncology

• ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors

  11/7/2018

  Updated Clinical Data Presented at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting in Washington, D.C.

• Alexo Therapeutics Changes Name to ALX Oncology

  6/22/2018

  The new name and logo will differentiate ALX Oncology (ALX) from other companies in the field as the Company advances its clinical programs.

• Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma

  6/4/2018

  Alexo Therapeutics presented data from the first-in-human Phase 1 study of its lead candidate, ALX148, at the American Society of Clinical Oncology (ASCO) Annual Meeting.

• Alexo Therapeutics Initiates ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors and Lymphoma

  5/17/2018

  Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced it has initiated ALX148 combination dosing with targeted antibody therapies in its Phase 1 clinical program in patients with advanced solid tumors and lymphoma.